Search results
5 days ago · Nicholas Turner, Cristina Saura, Philippe Aftimos, Evelyn van den Tweel, Mayke Oesterholt, Norbert Koper, Marco Colleoni, Emilie Kaczmarek, Kevin Punie, Xinni Song, Anne Armstrong, Giulia Bianchi, Agostina Stradella, Sylvain Ladoire, Joline Si Jing Lim, Nathalie Quenel-Tueux, Tira J. Tan, Santiago Escrivá-de-Romaní, Joyce O'Shaughnessy ...
Jan 1, 2023 · INTRODUCTION. Margetuximab-cmkb is an Fc-engineered anti–human epidermal growth factor receptor 2 (anti-HER2) immunoglobulin G monoclonal antibody that targets the same epitope as trastuzumab, with similar antiproliferative effects. 1,2 Compared with trastuzumab, margetuximab was designed to increase binding affinity (in vitro) for activating Fcγ receptor (FcγR) CD16A (FcγRIIIa) and ...
- 10.1200/JCO.21.02937
- 2023/01/01
- J Clin Oncol. 2023 Jan 10; 41(2): 198-205.
Dr Saura reported receiving personal fees from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, F. Hoffmann-La Roche Ltd, Genomic Health, Merck, Sharp and Dohme España SA, Novartis, Odonate Therapeutics, Pfizer, Philips HealthWork, Pierre Fabre, prIME Oncology, Puma, Synthon, and Sanofi Aventis outside the submitted work.
May 29, 2024 · Two hundred seventy-three patients (53%) reported amenorrhea at enrollment, of whom 94% resumed menses within 12 months. Among 497 patients evaluable for pregnancy, 368 (74%) reported at least one pregnancy.
Jan 22, 2021 · Design, Setting, and Participants. The SOPHIA phase 3 randomized open-label trial of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy enrolled 536 patients from August 26, 2015, to October 10, 2018, at 166 sites in 17 countries.
- Hope S. Rugo, Seock Ah Im, Fatima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Ma...
- 10.1001/jamaoncol.2020.7932
- 2021
- JAMA Oncol. 2021 Apr; 7(4): 1-12.
Aug 10, 2024 · Hatem A Azim Jr 1 2 , Samuel M Niman 3 4 , Ann H Partridge 5 6 , Isabelle Demeestere 7 8 , Monica Ruggeri 9 , Marco Colleoni 10 , Cristina Saura 11 12 , Chikako Shimizu 13 , Anna B Saetersdal 14 , Judith R Kroep 15 16 , Audrey Mailliez 17 , Ellen Warner 18 19 , Virginia F Borges 20 , Frédéric Amant 21 22 23 , Andrea Gombos 24 , Akemi Kataoka 25 , Christine Rousset-Jablonski 26 , Simona ...
Background and Purpose—Since demonstration of the benefit of endovascular treatment (EVT) in acute ischemic stroke patients with proximal arterial occlusion, stroke care systems need to be reorganized to deliver EVT in a timely and equitable way. We analyzed differences in the access to EVT by geographical areas in Catalonia, a territory with a highly decentralized stroke model. Methods—We ...
